- Home
- TELA vs ANL Comparison
TELA vs ANL Comparison
Compare TELA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TELA
- ANL
- Stock Information
- Founded
- TELA 2012
- ANL 2004
- Country
- TELA United States
- ANL Cayman Islands
- Employees
- TELA N/A
- ANL N/A
- Industry
- TELA Medical/Dental Instruments
- ANL
- Sector
- TELA Health Care
- ANL
- Exchange
- TELA Nasdaq
- ANL Nasdaq
- Market Cap
- TELA 60.6M
- ANL 61.8M
- IPO Year
- TELA 2019
- ANL 2023
- Fundamental
- Price
- TELA $1.29
- ANL $1.40
- Analyst Decision
- TELA Buy
- ANL Hold
- Analyst Count
- TELA 3
- ANL 1
- Target Price
- TELA $5.33
- ANL N/A
- AVG Volume (30 Days)
- TELA 96.8K
- ANL 9.0K
- Earning Date
- TELA 11-13-2025
- ANL 11-07-2025
- Dividend Yield
- TELA N/A
- ANL N/A
- EPS Growth
- TELA N/A
- ANL N/A
- EPS
- TELA N/A
- ANL N/A
- Revenue
- TELA $75,323,000.00
- ANL N/A
- Revenue This Year
- TELA $25.72
- ANL N/A
- Revenue Next Year
- TELA $22.03
- ANL N/A
- P/E Ratio
- TELA N/A
- ANL N/A
- Revenue Growth
- TELA 16.34
- ANL N/A
- 52 Week Low
- TELA $0.86
- ANL $1.10
- 52 Week High
- TELA $3.26
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- TELA 35.65
- ANL 36.83
- Support Level
- TELA $1.13
- ANL $1.30
- Resistance Level
- TELA $1.51
- ANL $1.59
- Average True Range (ATR)
- TELA 0.09
- ANL 0.11
- MACD
- TELA -0.02
- ANL -0.02
- Stochastic Oscillator
- TELA 37.21
- ANL 32.56
About TELA TELA Bio Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.